Uss Investment Management LTD Has Decreased Mondelez Intl (MDLZ) Position By $37.74 Million; Carmignac Gestion Has Increased Chemocentryx (CCXI) Stake

Mondelez International, Inc. (NASDAQ:MDLZ) Logo

Carmignac Gestion increased Chemocentryx Inc (CCXI) stake by 60.54% reported in 2019Q1 SEC filing. Carmignac Gestion acquired 741,210 shares as Chemocentryx Inc (CCXI)’s stock declined 38.33%. The Carmignac Gestion holds 1.97 million shares with $27.30 million value, up from 1.22 million last quarter. Chemocentryx Inc now has $381.54M valuation. The stock decreased 3.82% or $0.26 during the last trading session, reaching $6.55. About 816,080 shares traded or 60.33% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since August 15, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting

Uss Investment Management Ltd decreased Mondelez Intl Inc (MDLZ) stake by 28.08% reported in 2019Q1 SEC filing. Uss Investment Management Ltd sold 770,172 shares as Mondelez Intl Inc (MDLZ)’s stock rose 3.58%. The Uss Investment Management Ltd holds 1.97M shares with $98.42 million value, down from 2.74 million last quarter. Mondelez Intl Inc now has $77.37 billion valuation. The stock increased 0.85% or $0.45 during the last trading session, reaching $53.65. About 3.40 million shares traded. Mondelez International, Inc. (NASDAQ:MDLZ) has risen 24.40% since August 15, 2018 and is uptrending. It has outperformed by 24.40% the S&P500. Some Historical MDLZ News: 16/04/2018 – MONDELEZ SAYS $76M 6.5% NOTES DUE 2031 TENDERED; 02/04/2018 – Mondelēz International Announces Cash Tender Offer and Consent Solicitation; 02/04/2018 – Mondelez CEO Dirk Van de Put 2017 Total Compensation $42.4M; 07/05/2018 – MONDELEZ – ISSUED $2.5 BLN IN FIXED RATE NOTES DUE 2020 , FIXED RATE NOTES DUE 2023 , FIXED RATE NOTES DUE 2028 AND FIXED RATE NOTES DUE 2048; 27/04/2018 – Mondelez: Alviti to Succeed Karen May on June 11; 01/05/2018 – MONDELEZ MAINTAINS 2018 OUTLOOK FOR ORGANIC NET REV; 01/05/2018 – Mondelez 1Q North America Rev Down 1.3%; 16/04/2018 – Mondelez Announces Early Tender Results of Its Cash Tender Offer and Consent Solicitation; 03/05/2018 – Moody’s Assigns Baa1 To Mondelez Usd $2.5 Billion Notes Offering; 11/04/2018 – Mondelēz International Reports Rapid Growth of Cocoa Life Sustainable Sourcing Program

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates – Nasdaq” on August 05, 2019, also Seekingalpha.com with their article: “ChemoCentryx down 16% after Q2 revenue miss – Seeking Alpha” published on August 06, 2019, Finance.Yahoo.com published: “ChemoCentryx Inc (CCXI) Q2 2019 Earnings Call Transcript – Yahoo Finance” on August 08, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019 – Nasdaq” published on July 31, 2019 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx, Inc. 2019 Q2 – Results – Earnings Call Slides – Seeking Alpha” with publication date: August 06, 2019.

Among 2 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx has $2400 highest and $22 lowest target. $23’s average target is 251.15% above currents $6.55 stock price. ChemoCentryx had 4 analyst reports since March 12, 2019 according to SRatingsIntel. As per Tuesday, March 12, the company rating was maintained by H.C. Wainwright. FBR Capital upgraded the shares of CCXI in report on Wednesday, March 27 to “Buy” rating.

Investors sentiment increased to 1.44 in 2019 Q1. Its up 0.51, from 0.93 in 2018Q4. It increased, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. 643 are held by Qs Investors Ltd Llc. Metropolitan Life Insur Co, New York-based fund reported 42,380 shares. Retail Bank Of America De invested in 0% or 92,817 shares. Sio Cap Mgmt Llc holds 1.99% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 530,175 shares. Element Cap Ltd accumulated 0.01% or 11,906 shares. Zebra Capital Mgmt Ltd owns 0.1% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 12,853 shares. Parametric Portfolio Llc reported 55,490 shares or 0% of all its holdings. Aqr Cap Mngmt Ltd Co holds 22,364 shares. California Public Employees Retirement Sys owns 67,452 shares. Vanguard Grp Inc Inc Inc invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Jacobs Levy Equity Management owns 51,190 shares or 0.01% of their US portfolio. Art Advisors Ltd accumulated 23,876 shares. Dekabank Deutsche Girozentrale invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Ny State Common Retirement Fund owns 25,400 shares. 310,007 are owned by Northern Trust.

Carmignac Gestion decreased Albemarle Corp (NYSE:ALB) stake by 753,546 shares to 79,222 valued at $6.50 million in 2019Q1. It also reduced Qiagen N.V. stake by 210,841 shares and now owns 80,191 shares. Bristow Group Inc (NYSE:BRS) was reduced too.

Uss Investment Management Ltd increased Marsh & Mclennan Cos Inc (NYSE:MMC) stake by 12,432 shares to 2.18M valued at $204.55 million in 2019Q1. It also upped Cae Inc (NYSE:CAE) stake by 23,788 shares and now owns 6.01 million shares. Alibaba Group Hldg Ltd (NYSE:BABA) was raised too.

Investors sentiment decreased to 0.99 in Q1 2019. Its down 0.08, from 1.07 in 2018Q4. It is negative, as 54 investors sold MDLZ shares while 399 reduced holdings. 127 funds opened positions while 321 raised stakes. 1.04 billion shares or 0.32% less from 1.04 billion shares in 2018Q4 were reported. Andra Ap reported 111,100 shares. Price T Rowe Assoc Md holds 0.08% of its portfolio in Mondelez International, Inc. (NASDAQ:MDLZ) for 11.08 million shares. Loeb owns 675 shares for 0% of their portfolio. Old Second National Bank & Trust Of Aurora invested 0.13% of its portfolio in Mondelez International, Inc. (NASDAQ:MDLZ). Tci Wealth Advsr Incorporated has 0.13% invested in Mondelez International, Inc. (NASDAQ:MDLZ) for 6,102 shares. 11,877 were accumulated by Carroll Financial. Guggenheim Cap Ltd Com holds 641,049 shares. Tiedemann Limited Liability Corporation accumulated 16,018 shares. World Asset Mngmt holds 0.26% or 100,562 shares. Scotia Cap owns 73,818 shares for 0.05% of their portfolio. 346,322 were accumulated by Community Tru Invest. Credit Agricole S A stated it has 1,800 shares or 0% of all its holdings. Boston Advisors Lc holds 12,827 shares or 0.03% of its portfolio. Bank & Trust owns 1.13M shares. Invest Management Of Virginia Limited Liability Company owns 9,319 shares for 0.11% of their portfolio.

Among 3 analysts covering Mondelez Int`l (NASDAQ:MDLZ), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mondelez Int`l has $6200 highest and $51 lowest target. $59’s average target is 9.97% above currents $53.65 stock price. Mondelez Int`l had 7 analyst reports since March 16, 2019 according to SRatingsIntel. As per Wednesday, July 31, the company rating was maintained by Buckingham Research. On Wednesday, July 31 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The stock has “Outperform” rating by Credit Suisse on Wednesday, July 31. Barclays Capital maintained Mondelez International, Inc. (NASDAQ:MDLZ) rating on Tuesday, March 19. Barclays Capital has “Buy” rating and $51 target.

More notable recent Mondelez International, Inc. (NASDAQ:MDLZ) news were published by: Nasdaq.com which released: “What’s in the Offing for Mondelez’s (MDLZ) Q2 Earnings? – Nasdaq” on July 24, 2019, also Nasdaq.com with their article: “First Week of MDLZ March 2020 Options Trading – Nasdaq” published on July 23, 2019, Nasdaq.com published: “Mondelez (MDLZ) Q2 Earnings Match Estimates – Nasdaq” on July 30, 2019. More interesting news about Mondelez International, Inc. (NASDAQ:MDLZ) were released by: Nasdaq.com and their article: “Apple (AAPL) Beats on Surprise China Numbers; Plus EA, MDLZ – Nasdaq” published on July 30, 2019 as well as Nasdaq.com‘s news article titled: “After-Hours Earnings Report for July 30, 2019 : AAPL, AMGN, GILD, MDLZ, CELG, PSA, AMD, ALL, EQR, OKE, EA, VRSK – Nasdaq” with publication date: July 30, 2019.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *